Exactech Announces the Sale of Its Dental Biologic Assets to Salvin Dental Specialties

Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder and spine, announced today the sale of substantially all of the assets of its dental biologics business to Salvin Dental Specialties, through its Salvin Regenerative subsidiary. Salvin Dental is a privately held company doing business in more than 100 countries which develops, manufactures and markets regenerative biomaterials and surgical instrumentation specifically for implant dentistry. Financial terms were not disclosed.

“While it has been a pleasure to provide Exactech’s biologic innovations to the dental market for more than 10 years, we have made the strategic decision to focus more exclusively on our core orthopaedic business,” said Exactech’s Senior Vice President and General Manager of Spine and Biologics Bruce Thompson. “We have enjoyed a long-standing distribution relationship with Salvin, which gives us confidence that they will take good care of our dental customers in their pursuit of improving patient care.”

Exactech’s Dental Biologics Division supplies the dental market with leading dental biologic products including Optecure® and Oralife®. Optecure® Dental is an engineered bone graft for reconstruction and augmentation of deficient maxillary and mandibular alveolar ridges and dental intraosseous defects.

According to Founder and CEO Bob Salvin, Exactech has an exciting dental product line and this acquisition will provide Salvin with additional product depth and manufacturing capabilities.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.

An investment profile on Exactech may be found at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160104005223/en/